1-2 of 2
Anthony Viggiano, MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Richard R. Furman, MD, Sven de Vos, MD PhD, Jacqueline C. Barrientos, MD, Marshall T. Schreeder, MD, Ian W. Flinn, MD PhD, Jeff P. Sharman, MD, Thomas E Boyd, MD, Nathan Fowler, MD, John P. Leonard, MD, Kanti R. Rai, MD, Yeonhee Kim, PhD, Anthony Viggiano, MS, Thomas M. Jahn, MD PhD, Steven E. Coutre, MD
Journal: Blood
Blood (2014) 124 (21): 5653.
https://doi.org/10.1182/blood.V124.21.5653.5653
Published: 2014
Journal Articles

Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil/Rituximab (ChlR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Jacqueline C. Barrientos, MD, Steven E. Coutre, MD, Sven de Vos, MD PhD, Nina D. Wagner-Johnston, MD, Ian W. Flinn, MD PhD, Jeff P. Sharman, MD, Marshall T. Schreeder, MD, Thomas E Boyd, MD, Kanti R. Rai, MD, John P. Leonard, MD, Yeonhee Kim, PhD, Anthony Viggiano, MS, Thomas M. Jahn, MD PhD, Richard R. Furman, MD
Journal: Blood
Blood (2014) 124 (21): 3343.
https://doi.org/10.1182/blood.V124.21.3343.3343
Published: 2014